Form 4: C4 Therapeutics Director Kenneth Carl Anderson Acquires Stock Options
SEC Form 4 Filing
Director Kenneth Carl Anderson acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.
Summary
- On June 20, 2024, Kenneth Carl Anderson, a director of C4 Therapeutics, Inc. (CCCC), acquired stock options to purchase 32,500 shares of common stock at an exercise price of $4.05.
- The options vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the Board.
- Following the transaction, Anderson directly owns 32,500 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports an insider transaction. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor their investment decisions.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of stock option acquisition |
| 06/20/2025 | First possible vesting date for stock options |
| 06/19/2034 | Expiration date of the stock options |
| 06/21/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.